MedTrace Logo

ZETA : Prospective Observational Study

NCT03730558 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2025-01-22

No results posted yet for this study

Summary

Primary objective

\- Evaluate the efficacy in terms of progression-free survival (PFS) of aflibercept in combination with FOLFIRI in patients treated routinely for metastatic colorectal cancer (mCRC) after failure of treatment with oxaliplatin + EGFR.

Secondary objective

* Evaluate the efficacy of aflibercept in combination with FOLFIRI on the 2-year overall survival rate and the objective response rate.
* Evaluate the tolerance profile of aflibercept in combination with FOLFIRI.

* Observational study, national, multicenter, cohort, prospective without intervention on the therapeutic strategy.•

Conditions

Interventions

COMBINATION_PRODUCT

aflibercept + FOLFIRI

aflibercept + FOLFIRI

Sponsors & Collaborators

  • Recherche clinique

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-08
Primary Completion
2021-11-08
Completion
2021-11-08

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03730558 on ClinicalTrials.gov